ZEULIDE 3.75 mg, powder and solvent for injectable suspension with extended release bottle, 2 ml
Active ingredients: Leuprolide acetate, LEUPRORÉLINE
Commercialized according to BDPMDispensing in France: Prescription only
Powder and solvent for injectable suspension with extended releasebottle, 2 mlintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ZEULIDE 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée
- Pharmaceutical form
- poudre et solvant pour suspension injectable à libération prolongée
- Route of administration
- intramusculaire
- Presentation description
- 1 flacon en verre de poudre - 1 seringue préremplie en verre de 2 ml de solvant - 1 adaptateur en polycarbonate polyéthylène haute densité (PEHD) incluant 1 aiguille stérile
- Marketing authorisation holder
- BESINS HEALTHCARE FRANCE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Jan 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62479447CIP73016624CIP133400930166246Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LEUPRORÉLINEpoudre | 3,57 mg · un flacon | FT |
| ACÉTATE DE LEUPRORÉLINEpoudre | 3,75 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.